Novo Nordisk's new obesity pill, Amycretin, demonstrates significant weight loss potential, achieving 13.1% reduction in body weight in just three months, outperforming Wegovy.
The obesity pill works by stimulating the amylin hormone and targeting GLP-1 receptors. This mechanism may offer improved results compared to existing treatments like Wegovy.
Amycretin's oral dosage could revolutionize weight-loss treatments, contrasting with current injected options and potentially expanding the market significantly for consumers.
Early clinical trials indicate Amycretin's side effects were primarily gastrointestinal, similar to other weight-loss drugs, suggesting a tolerable safety profile for users.
Collection
[
|
...
]